Abstract:Rationale: The existence of primary and acquired drug resistance is the main obstacle for the effect of multi-kinase inhibitor sorafenib and regorafenib in advanced hepatocellular carcinoma (HCC). However, plenty of patients did not significantly benefit from sorafenib treatment and little is known about the mechanism of drug resistance. Methods: Laser capture microdissection was used to acquire matched normal liver and tumor tissues on formalin-fixed paraffin-embedded specimens collected before sorafenib therapy from the first surgery of 119 HCC patients. Ultra-deep sequencing (similar to 1000x) targeting whole exons of 440 genes in microdissected specimens and siRNA screen in 7 cell lines were performed to find mutations associated with differential responses to sorafenib. Patient-derived xenograft models were employed to determine the role of TPS3 in response to sorafenib. Lentiviruses harboring wild-type and c.G52C-mutant OCT4 were applied to explore the function of OCT4 in resistance to sorafenib. ChIP-PCR assay for analysis of OCT4 transcriptional activity was performed to explore the affinity with the KITLG promoter. Statistical analyses were used to associate levels of p53 and OCT4 with tumor features and patient outcomes. Results: Total 1,050 somatic mutations and 26 significant driver genes were identified. SiRNA screening in 7 HCC cell lines was further performed to identify mutations associated with differential responses to sorafenib. A recurrent nonsynonymous mutation c.G52C in OCT4 (OCT4(mut)) was strongly associated with good response to sorafenib, whereas the stop-gain mutation in TPS3 showed the opposite outcome both in vitro and in vivo. OCT4(wt)-induced stem cell factor (encoded by KITLG gene, SCF) expression and cross-activation of c-KIT/FLT3-BRAF signals were identified indispensably for sorafenib resistance, which could be reversed by the combination of c-KIT tyrosine kinase inhibitors or neutralizing antibody against SCF. Mechanistically, an OCT4 binding site in upstream of KITLG promoter was identified with a higher affinity to wildtype of OCT4 rather than G52C-mutant form, which is indispensable for OCT4-induced expression of KITLG and sorafenib resistance. Conclusion: Our study reported a novel somatic mutation in OCT4 (c.G52C) responsible for the sorafenib effect, and also shed new light on the treatment of HCC through the combination of specific tyrosine kinase inhibitors according to individual genetic patterns.

Corrigendum to “circumventing Intratumoral Heterogeneity to Identify Potential Therapeutic Targets in Hepatocellular Carcinoma” [J Hepatol 67 (2017) 293–301]

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Corrigendum: Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma

Corrigendum to 'genomic Sequencing Identifies WNK2 As a Driver in Hepatocellular Carcinoma and a Risk Factor for Early Recurrence' [J Hepatol 71 (2019) 1152-63].

Corrigendum To: "pkcα/zfp64/csf1 Axis Resets the Tumor Microenvironment and Fuels Anti-Pd1 Resistance in Hepatocellular Carcinoma" [J Hepatol 77 (2022) 163-176].

Circumventing Intratumoral Heterogeneity to Identify Potential Therapeutic Targets in Hepatocellular Carcinoma.

Corrigendum: Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Targeted Sequencing Reveals the Mutational Landscape Responsible for Sorafenib Therapy in Advanced Hepatocellular Carcinoma.

Corrigendum to "MR Features Based on LI-RADS Identify Cytokeratin 19 Status of Hepatocellular Carcinomas" [eur. J. Radiol. 113 (2019) 7-14].

Corrigendum to ‘predicting Post-Resection Recurrence by Integrating Imaging-Based Surrogates of Distinct Vascular Patterns of Hepatocellular Carcinoma’ (JHEP Reports 5 [2023] 100806)

Corrigendum: the Significance of Transarterial Chemo(embolization) Combined with Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

Corrigendum to ‘ramucirumab As Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy with Sorafenib: Patient-focused Outcome Results from the Randomised Phase III REACH Study’ [eur J Canc 81 (2017) 17–25]

Prognostic Comparative Genes Predict Targets for Sorafenib Combination Therapies in Hepatocellular Carcinoma

Correction: Corrigendum: Patient-specific Hepatocyte-Like Cells Derived from Induced Pluripotent Stem Cells Model Pazopanib-Mediated Hepatotoxicity

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

Corrigendum: Comparison of Clinical Outcomes Between Cone Beam CT-guided Thermal Ablation and Helical Tomotherapy in Pulmonary Metastases from Hepatocellular Carcinoma

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Corrigendum to "Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients"

Corrigendum to “system Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma”

Corrigendum: Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].